Anti-Lymphotoxin alpha [MLTA3698A (Pateclizumab)]

Absolute Antibody

Anti-Lymphotoxin alpha [MLTA3698A (Pateclizumab)]

7

This antibody has been shown to able to both block LTalpha-mediated signaling and selectively deplete LTalpha-expressing activated T and B cells, which has therapeutic applications in abrogating proinflammatory responses in rheumatoid arthritis (RA) pathology (Kennedy, 2014). Preliminary clinical trials demonstrated that administration of this antibody decreased serum levels of CXCL13, a biomarker of RA disease activity (Emu, 2012). In a phase II trial, this antibody had a trend for clinical effects on the symptoms of RA after 3 months of treatment, but the differences from placebo responses were not statistically significant (Kennedy, 2014). In a human peripheral blood mononuclear cell transplanted SCID mouse model of graft-versus-host disease, this antibody specifically depleted activated LTalpha-expressing human donor T and B cells, prolonging survival of the mice (Chiang, 2012). Finally, this antibody has been used to in FC and surface plasmon resonance analysis to characterise its interaction with the LTalpha ligand.

Flow Cytometry, Neutralisation/Blocking, Other Application

FC; SPR; block; deplete

Research Use Only

Monoclonal

MLTA3698A (Pateclizumab)

LTA

lymphotoxin alpha

LT; LT-alpha; lymphotoxin-alpha; TNF superfamily, member 1; TNFB; TNF-beta; TNFSF1; TNLG1E; truncated lymphotoxin alpha; tumor necrosis factor beta; tumor necrosis factor ligand 1E; tumor necrosis factor ligand superfamily member 1

Human

IgG1

Lymphotoxin-alpha

Human

This humanized antibody was derived from a mouse anti-human LT-alfa hybridoma mAb.

-20°C,2°C to 8°C

12352203